Du Pont's Neurolite approved by FDA

Article

Du Pont Merck Pharmaceuticalreceived approval last month from the Food and Drug Administrationfor Neurolite, a technetium-tagged brain SPECT imaging agent.Neurolite becomes the second brain SPECT agent on the market,joining Amersham's Ceretec, also a

Du Pont Merck Pharmaceuticalreceived approval last month from the Food and Drug Administrationfor Neurolite, a technetium-tagged brain SPECT imaging agent.Neurolite becomes the second brain SPECT agent on the market,joining Amersham's Ceretec, also a technetium-labeled agent. DuPont Merck, of North Billerica, MA, plans to begin shipping Neurolitein January. The product is indicated for brain perfusion studiesin stroke patients (SCAN 9/14/94).

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.